Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324598 | 0.87 | LCK (0.38) | LCKSRCCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18817126 | 0.81 | MAOA (0.36) | LCKSRCBRD9LMNA | |
| SCHEMBL18851718 | 0.79 | LCK (0.43) | LCKSRCBRD9 | |
| SCHEMBL18816974 | 0.74 | AKR1C2 (0.41) | LCKSRCBRD9LMNAHTT | |
| SCHEMBL18816932 | 0.71 | TP53 (0.33) | LCKLMNATP53HTT | |
| SCHEMBL18842705 | 0.70 | LCK (0.40) | LCKHSP90AA1HSP90AB1 | |
| SCHEMBL18817386 | 0.68 | AKT1 (0.36) | LCKSRCBRD9LMNA | |
| SCHEMBL17331860 | 0.67 | TRPV1 (0.40) | CYP2D6 | |
| SCHEMBL18844144 | 0.67 | TNF (0.32) | BRD9LMNATP53HTT | |
| SCHEMBL18816969 | 0.65 | EGFR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2023-01-12 | — | — | US | disclosed |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2023-01-12 | — | — | US | disclosed |
| EP-4086259-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3371190-B1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3371190-B1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11091491-B2 | Heterocyclic compounds as PI3K-y inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091491-B2 | Heterocyclic compounds as PI3K-y inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | disclosed |
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3371190-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2018-09-12 | — | — | EP | disclosed |
| US-10065963-B2 | Heterocyclic compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2018-09-04 | — | — | US | disclosed |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2017-05-11 | — | — | US | disclosed |
| WO-2017079519-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017079519-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773102-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | LCK 476/4885SRC 708/4885BRD9 1396/4885 |
| US-11091491-B2 | Heterocyclic compounds as PI3K-y inhibitors | PIK3R5, PIK3CA, PIK3CD | LCK 154/4885SRC 260/4885BRD9 1434/4885 |
| US-10472368-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | LCK 476/4885SRC 708/4885BRD9 1396/4885 |
| US-10065963-B2 | Heterocyclic compounds as PI3K-γ inhibitors | PIK3CD, PIK3CG, PIK3R5 | LCK 476/4885SRC 708/4885BRD9 1396/4885 |
| US-20200031837-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | LCK 154/4885SRC 260/4885BRD9 1434/4885 |
| US-20170129899-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | LCK 154/4885SRC 260/4885BRD9 1434/4885 |
| US-20230009843-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | LCK 154/4885SRC 260/4885BRD9 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.